XML 100 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1

License and Other Agreements (Details) € in Millions, $ in Millions	1 Months Ended						3 Months Ended	12 Months Ended			240 Months Ended
	Dec. 31, 2020 USD ($)	Apr. 30, 2020	Oct. 31, 2016 USD ($)	Jul. 31, 2014	Feb. 28, 2014 USD ($) kg	Apr. 30, 2008 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2004 USD ($)	Dec. 31, 2023 USD ($)
PARI Agreement
Collaboration Agreements
Initial term of contract manufacturing agreement				15 years
Additional term of contract manufacturing agreement				5 years
PARI Agreement | Minimum
Collaboration Agreements
Written notice period required for termination of contract manufacturing agreement				1 year
PARI Agreement | Milestone, New Drug Application
Collaboration Agreements
PARI milestone upon FDA approval | €						€ 1.0
PARI Agreement | Milestone, FDA Approval
Collaboration Agreements
PARI milestone upon FDA approval | €						1.5
PARI Agreement | Milestone, EMA Approval
Collaboration Agreements
PARI milestone upon FDA approval | €						€ 0.5
PPD Development, L.P. Agreement
Collaboration Agreements
Initial term of clinical development services agreement		5 years
Written notice termination term of clinical development services agreement		30 days
License Agreement with AstraZeneca
Collaboration Agreements
Collaborative arrangement, additional payment							$ 12.5
Royalty payment			$ 35.0
License Agreement with AstraZeneca | Maximum
Collaboration Agreements
Aggregate payment upon the achievement of certain clinical milestones			60.0
Additional contingent payments upon second indication to develop INS1007			42.5
License Agreement with AstraZeneca | License and Service
Collaboration Agreements
Annual net sales			$ 1,000.0
License Agreement with AstraZeneca | Research and development expenses
Collaboration Agreements
Upfront payment							$ 30.0
Phase 3 study payment	$ 12.5
Resilience Biotechnologies
Collaboration Agreements
Initial term of contract manufacturing agreement					5 years
Written notice period required for termination of contract manufacturing agreement					2 years
Manufacturing scale (in kilograms) | kg					200
Period of each automatic renewal of contract manufacturing agreement					2 years
Minimum obligation					$ 6.0
CFFT
Collaboration Agreements
Compensation earned under research funding agreements with CFFT									$ 2.2	$ 1.7
Royalty payable on approval of ARIKAYCE as commercialized drug								$ 13.4			$ 13.4
Royalty expense paid for ARIKAYCE approval											7.4
Period for meeting sales milestones for additional royalty payments								5 years
Royalty payable on meeting certain sales milestones								$ 3.9			$ 3.9
Additional global sales milestone payments								$ 1.7

X

- Definition

Additional Royalty Expense

+ References

No definition available.

+ Details

Name:	insm_AdditionalRoyaltyExpense
Namespace Prefix:	insm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of royalty payments if entity meets certain milestones under a research and development agreement.

+ References

No definition available.

+ Details

Name:	insm_AdditionalRoyaltyGuaranteesCommitmentsAmount
Namespace Prefix:	insm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents the additional extension period of contract manufacturing agreement.

+ References

No definition available.

+ Details

Name:	insm_AdditionalTermOfContractManufacturingAgreement
Namespace Prefix:	insm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Aggregate additional series of contingent milestone payments if selects to develop for second indication.

+ References

No definition available.

+ Details

Name:	insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication
Namespace Prefix:	insm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Collaborative Arrangement, Additional Payment

+ References

No definition available.

+ Details

Name:	insm_CollaborativeArrangementAdditionalPayment
Namespace Prefix:	insm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative Arrangement, Milestone Payment

+ References

No definition available.

+ Details

Name:	insm_CollaborativeArrangementMilestonePayment
Namespace Prefix:	insm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative Arrangement, Phase 3 Study Payment

+ References

No definition available.

+ Details

Name:	insm_CollaborativeArrangementPhase3StudyPayment
Namespace Prefix:	insm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of upfront payment paid during the period under collaborative arrangement.

+ References

No definition available.

+ Details

Name:	insm_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	insm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the minimum obligation due under the terms of the agreement.

+ References

No definition available.

+ Details

Name:	insm_CommercialServicesAgreementMinimumObligation
Namespace Prefix:	insm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Contract Manufacturing Agreement, Rate Of Manufacturing

+ References

No definition available.

+ Details

Name:	insm_ContractManufacturingAgreementRateOfManufacturing
Namespace Prefix:	insm_
Data Type:	dtr-types:massItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Initial Term of Clinical Development Services Agreement

+ References

No definition available.

+ Details

Name:	insm_InitialTermOfClinicalDevelopmentServicesAgreement
Namespace Prefix:	insm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the initial period of contract manufacturing agreement.

+ References

No definition available.

+ Details

Name:	insm_InitialTermOfContractManufacturingAgreement
Namespace Prefix:	insm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Aggregate payment upon the achievement of certain clinical milestones.

+ References

No definition available.

+ Details

Name:	insm_PaymentsUponAchievementOfClinicalMilestonesAmount
Namespace Prefix:	insm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Period for meeting sales milestones for additional royalty payments after the drug is commercialized.

+ References

No definition available.

+ Details

Name:	insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments
Namespace Prefix:	insm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the period of each automatic renewal of contract manufacturing agreement.

+ References

No definition available.

+ Details

Name:	insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement
Namespace Prefix:	insm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the written notice period required for termination of contract manufacturing agreement by either party.

+ References

No definition available.

+ Details

Name:	insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement
Namespace Prefix:	insm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Written Notice Termination Term Of Clinical Development Services Agreement

+ References

No definition available.

+ Details

Name:	insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement
Namespace Prefix:	insm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount the entity has committed to make for future royalty guarantees.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 928
-SubTopic 440
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483119/928-440-50-1

+ Details

Name:	us-gaap_RoyaltyGuaranteesCommitmentsAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	insm_MilestonePaymentAxis=insm_MilestoneNewDrugApplicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	insm_MilestonePaymentAxis=insm_MilestoneFDAApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	insm_MilestonePaymentAxis=insm_MilestoneEMAApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=insm_PPDDevelopmentLPAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: